Want to see IONS full AI Analyst Report?
Total Valuation
Ionis Pharmaceuticals has a market cap or net worth of $9.63B. The enterprise value is $14.15B.
Market Cap$9.63B
Enterprise Value$14.15B
Share Statistics
Ionis Pharmaceuticals has 165,262,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding165,262,560
Owned by Insiders0.75%
Owned by Institutions0.28%
Financial Efficiency
Ionis Pharmaceuticals’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -11.96%.
Return on Equity (ROE)-0.78
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-11.96%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee673.32K
Profits Per Employee-272.03K
Employee Count1,402
Asset Turnover0.27
Inventory Turnover1.59
Valuation Ratios
The current PE Ratio of Ionis Pharmaceuticals is ―. Ionis Pharmaceuticals’s PEG ratio is 1.53.
PE Ratio―
PS Ratio13.41
PB Ratio25.88
Price to Fair Value25.88
Price to FCF-39.55
Price to Operating Cash Flow-10.27
PEG Ratio1.53
Income Statement
In the last 12 months, Ionis Pharmaceuticals had revenue of 944.00M and earned -381.00M in profits. Earnings per share was -2.38.
Revenue944.00M
Gross Profit928.00M
Operating Income-382.00M
Pretax Income-380.00M
Net Income-381.00M
EBITDA-286.75M
Earnings Per Share (EPS)-2.38
Cash Flow
In the last 12 months, operating cash flow was -910.63M and capital expenditures -60.63M, giving a free cash flow of -971.26M billion.
Operating Cash Flow-910.63M
Free Cash Flow-971.26M
Free Cash Flow per Share-5.88
Dividends & Yields
Ionis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change33.37%
50-Day Moving Average75.30
200-Day Moving Average76.07
Relative Strength Index (RSI)25.51
Average Volume (3m)2.88M
Important Dates
Ionis Pharmaceuticals upcoming earnings date is Aug 5, 2026, Before Open (Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Ionis Pharmaceuticals as a current ratio of 3.83, with Debt / Equity ratio of 415.32%
Current Ratio3.83
Quick Ratio3.81
Debt to Market Cap0.19
Net Debt to EBITDA-7.82
Interest Coverage Ratio-4.22
Taxes
In the past 12 months, Ionis Pharmaceuticals has paid 1.00M in taxes.
Income Tax1.00M
Effective Tax Rate>-0.01
Enterprise Valuation
Ionis Pharmaceuticals EV to EBITDA ratio is -51.96, with an EV/FCF ratio of -46.56.
EV to Sales15.78
EV to EBITDA-51.96
EV to Free Cash Flow-46.56
EV to Operating Cash Flow-55.48
Balance Sheet
Ionis Pharmaceuticals has $1.92B in cash and marketable securities with $2.04B in debt, giving a net cash position of -$121.84M billion.
Cash & Marketable Securities$1.92B
Total Debt$2.04B
Net Cash-$121.84M
Net Cash Per Share-$0.74
Tangible Book Value Per Share$3.06
Margins
Gross margin is 98.35%, with operating margin of -40.47%, and net profit margin of -40.36%.
Gross Margin98.35%
Operating Margin-40.47%
Pretax Margin-40.25%
Net Profit Margin-40.36%
EBITDA Margin-30.38%
EBIT Margin-32.52%
Analyst Forecast
The average price target for Ionis Pharmaceuticals is $94.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$94.11
Price Target Upside24.30% Upside
Analyst ConsensusStrong Buy
Analyst Count19
Revenue Growth Forecast47.40%
EPS Growth Forecast32.85%